1 Information has been obtained on the outcome of 448 completed pregnancies in mothers who had been given bromocriptine at some stage in the early weeks of pregnancy. 2 The frequencies of spontaneous abortions, twin pregnancies and malformations have been compared with those reported for 'normal' populations. 3 Based on this limited material, we conclude that the use of bromocriptine to restore fertility in hyperprolactinaemic women is not associated with an increased risk of abortion, multiple pregnancy or the occurrence of malformations in the infants.
1Out of 805 previously infertile women in whom pregnancy was achieved on bromocriptine treatment, 137 were diagnosed as having pituitary tumours. 2 In nine of these, tumour-related complications occurred during pregnancy, chiefly visual field impairment. Surgical intervention was considered necessary in two patients. In a third patient reinstitution of bromocriptine produced remission of symptoms. 3 Although the frequency of serious complications was low, the present state of knowledge indicates that surgery or irradiation of pituitary tumours should be preferred, at least as the first line of treatment, for patients contemplating pregnancy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.